These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 12226786)

  • 1. [Rheumatology on the move].
    Dörner T; Siegenthaler W; Burmester GR
    Dtsch Med Wochenschr; 2002 Sep; 127(37):1875. PubMed ID: 12226786
    [No Abstract]   [Full Text] [Related]  

  • 2. [New treatments for rheumatoid arthritis].
    Girault V; Flipo RM
    Soins; 2004 Sep; (688):37-8. PubMed ID: 15515847
    [No Abstract]   [Full Text] [Related]  

  • 3. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 4. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Schiff MH
    Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
    [No Abstract]   [Full Text] [Related]  

  • 6. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 8. [Report of the DGRh (German Society for Rheumatology)].
    Z Rheumatol; 2011 Jul; 70(5):441-3. PubMed ID: 21732235
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
    Cohen SB
    Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rheumatology update--II. Summary of clinically significant current knowledge and outlook of prospective relevant trends in etiopathogenic research, diagnostic methods and therapeutic possibilities].
    Hein G; Bolwin R; Bräuer R; Eidner T; Franke S; Oelzner P; Sprott H
    Med Klin (Munich); 1996 Apr; 91 Suppl 1():56-64. PubMed ID: 8657087
    [No Abstract]   [Full Text] [Related]  

  • 11. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 12. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Bijlsma JW; Burmester GR; Cronstein B; Keystone EC; Kavanaugh A; Klareskog L
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii2-7. PubMed ID: 12379612
    [No Abstract]   [Full Text] [Related]  

  • 13. [Report of the DRL].
    Z Rheumatol; 2011 Jul; 70(5):444. PubMed ID: 21732236
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biological agents for therapy of rheumatoid arthritis--overview].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
    [No Abstract]   [Full Text] [Related]  

  • 15. [When are "biologics" indicated?].
    MMW Fortschr Med; 2006 Apr; 148(17):10. PubMed ID: 16711479
    [No Abstract]   [Full Text] [Related]  

  • 16. [Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors. Pharmacotherapy Committee of the German Society of Rheumatology].
    Z Rheumatol; 2000 Aug; 59(4):291-2. PubMed ID: 11013988
    [No Abstract]   [Full Text] [Related]  

  • 17. Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs.
    Konttinen YT; Seitsalo S; Lehto M; Santavirta S
    Acta Orthop; 2005 Oct; 76(5):614-9. PubMed ID: 16263606
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on rheumatology: part 1.
    Neal-Boylan L
    Home Healthc Nurse; 2009 May; 27(5):286-96; quiz 297-8. PubMed ID: 19448496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 'alphabet' of rheumatoid arthritis treatment.
    Capriotti T
    Medsurg Nurs; 2004 Dec; 13(6):420-8. PubMed ID: 15714747
    [No Abstract]   [Full Text] [Related]  

  • 20. The 2005 International Symposium on Advances in Targeted Therapies: what have we learned in the 2000s and where are we going?
    Maini RN
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4():iv106-8. PubMed ID: 16239377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.